Three-dimensional Nuclear Telomere Organization in Multiple Myeloma.
Multiple myeloma (MM) is preceded by monoclonal gammopathy of undetermined significance (MGUS). Up to date, it is difficult to predict an individual's time to disease progression and the treatment response. To examine whether the nuclear telomeric architecture will unravel some of these questions, we carried out. Three-dimensional (3D) telomere analysis on samples from patients diagnosed with MGUS and MM, as well as from patients who went into relapse. Telomere signal intensity, number of telomere aggregates, nuclear volume, and the overall nuclear telomere distribution (a/c ratio) were analyzed. The telomeric profiles allowed for the differentiation of the disease stages. The telomeric profiles of myeloma cells obtained from blood and bone marrow aspirates were identical. Based on this study, we discuss the use of 3D telomere profiling as a potential future tool for risk stratification and personalized treatment decisions.
Manitoba Institute of Cell Biology, University of Manitoba, CancerCare Manitoba, Winnipeg, Manitoba, Canada.
Ludger
L
Klewes
Manitoba Institute of Cell Biology, University of Manitoba, CancerCare Manitoba, Winnipeg, Manitoba, Canada.
Rhea
R
Vallente
Manitoba Institute of Cell Biology, University of Manitoba, CancerCare Manitoba, Winnipeg, Manitoba, Canada.
Eric
E
Dupas
Manitoba Institute of Cell Biology, University of Manitoba, CancerCare Manitoba, Winnipeg, Manitoba, Canada ; Département de Biochimie, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Carolin
C
Brand
Manitoba Institute of Cell Biology, University of Manitoba, CancerCare Manitoba, Winnipeg, Manitoba, Canada ; University of Dortmund, Dortmund, North Rhine-Westphalia, Germany.
Dietrich
D
Grün
Manitoba Institute of Cell Biology, University of Manitoba, CancerCare Manitoba, Winnipeg, Manitoba, Canada.
Amanda
A
Guffei
Manitoba Institute of Cell Biology, University of Manitoba, CancerCare Manitoba, Winnipeg, Manitoba, Canada ; Division of Medical Oncology, Department of Internal Medicine, Prince of Songkla University Hospital, Hat Yai, Songkla, Thailand.
Chirawadee
C
Sathitruangsak
Manitoba Institute of Cell Biology, University of Manitoba, CancerCare Manitoba, Winnipeg, Manitoba, Canada.
Julius A
JA
Awe
Manitoba Institute of Cell Biology, University of Manitoba, CancerCare Manitoba, Winnipeg, Manitoba, Canada.
Alexandra
A
Kuzyk
Manitoba Institute of Cell Biology, University of Manitoba, CancerCare Manitoba, Winnipeg, Manitoba, Canada.
Daniel
D
Lichtensztejn
United Laboratories, Tartu University Hospital, Tartu, Estonia.
Pille
P
Tammur
United Laboratories, Tartu University Hospital, Tartu, Estonia.
Tiiu
T
Ilus
United Laboratories, Tartu University Hospital, Tartu, Estonia.
Anu
A
Tamm
Hematology and Oncology Clinic, Tartu University Hospital, Tartu, Estonia.
Mari
M
Punab
Haematology, CancerCare Manitoba, Winnipeg, Manitoba, Canada.
Morel
M
Rubinger
Haematology, CancerCare Manitoba, Winnipeg, Manitoba, Canada.
Adebayo
A
Olujohungbe
Manitoba Institute of Cell Biology, University of Manitoba, CancerCare Manitoba, Winnipeg, Manitoba, Canada ; Physiology, Manitoba Institute of Cell Biology, Winnipeg, Manitoba, Canada.
Sabine
S
Mai